



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board



	<b>Agenda Item</b>	<b>2.3 (ii)</b>
--	--------------------	-----------------

<b>Freedom of Information Status</b>	Open
<b>Reporting Committee</b>	Performance and Finance Committee
<b>Author</b>	Liz Stauber, Head of Corporate Governance
<b>Chaired by</b>	Reena Owen, Independent Member
<b>Lead Executive Director (s)</b>	Darren Griffiths, Interim Director of Finance
<b>Date of last meeting</b>	27 October 2020

**Summary of key matters considered by the committee and any related decisions made:**

- **Monthly Performance Report**

This was the first report since the health board had been de-escalated from targeted intervention to enhanced monitoring. Covid-19 cases were continuing to rise but at the point at which the report had been drafted, there were more cases outside of hospitals rather than in beds than there had been in the first wave. The health board was only one of two in Wales still meeting the red ambulance release target but there had been an increase in one-hour ambulance handover delays, just not to the levels seen pre-Covid-19. The four-hour performance for unscheduled care had been around 80% from May 2020 to August 2020 but this had deteriorated to 76% in September 2020 due to the pressures of emergency admissions. With the exception of *staph.aureus*, the number of cases within the reported infection areas had reduced. An increase in GP referrals had been evident for planned care following a dip during the first wave of Covid-19. As a result, the waiting list was now growing in size, not just length.

- **Follow-Ups Not Booked**

Work was continuing in relation to innovation and delivery as well as the development of more business intelligence. There was also a significant amount of work taking place on a national level. The numbers of follow-ups not booked had been improving until the start of Covid-19. Services were now restarting as part of the reset and recovery work. Some external funding had been received for initiatives such as 'see on symptom', eye care and 'patient initiated follow-up'. A dedicated work programme was now in place.

**Key risks and issues/matters of concern of which the board needs to be made aware:**

- **Cancer Performance**

The urgent suspected cancer and non-urgent suspected cancer performance for August 2020 was 91% with 10 and six breaches respectively. The single cancer pathway performance for the same period was 80%. Although targets were being achieved and performance was good, a significant backlog in cases remained and it was unclear the proportion of these which were cancerous and those which were not. One of the main areas of concern was endoscopy as services had to be stood down as part of the response to first wave of Covid-19 and while it was now back up and running, it was at 50% activity levels although additional waiting list initiative sessions had been arranged. Another was theatre capacity, particularly in urology due to the volume needing diagnostic surgical procedures, and while extra lists were in place, it

would take a while before performance caught up and the second peak was causing additional challenges. A further update would be received in December 2020.

- **Financial Position**

A population share of £48.2m had been received from Welsh Government to cover Covid-19 expenditure along with notification of other potential funding opportunities in a phased way. The cumulative overspend for the first six months of the year was £12.8m and this would be subject to a scrutiny review with Welsh Government and the NHS Wales Financial Delivery Unit, in addition to a peer review by Aneurin Bevan University Health Board. Once these had taken place, it was anticipated a control total for the year would be allocated. The last report to the committee set out a year-end forecast of a £96.1m deficit. Following the submission of the quarter three/four operational delivery plan, this had reduced to £26.43m, which was the original £24.4m and an additional £2m for the transcatheter aortic valve insertion (TAVI) service.

**Delegated action by the committee:**

No delegated action was taken by the committee.

**Main sources of information received:**

- Performance report;
- Cancer performance report;
- Finance report;
- Follow-ups not booked report.

**Highlights from sub-groups reporting into this committee:**

No reports received from sub-groups.

**Matters referred to other committees:**

No items referred to other committees.

**Date of next meeting**

24 November 2020